A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...

The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...

In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Alumis: Top-line ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where aTyr Pharma, Inc. (NASDAQ:ATYR) stands against other hot biotech stocks under $5.

Large pharmaceutical companies are entering a period of renewed relevance as therapeutic innovation accelerates, particularly ...

AI is no longer a distant concept; it is reshaping industries today. For pharmaceutical companies, the question is clear: how ...

The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public ...

The June agreement established a fixed revenue-sharing model, with TME Pharma receiving a “larger share of future licensing ...

Discover how drugs prevent, cure, and alleviate ailments. Learn about over-the-counter vs. prescription drugs and the pharmaceutical industry's impact on healthcare.